^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Characterization of the Novel and Specific PI3Ka Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Excerpt:
Most of the tumor models that carried a PIK3CA mutation or amplification responded to NVP-BYL719 (response defined as T/C < 20%). In contrast, in most of the tumor models that carried a PTEN mutation or were PIK3CA wild type, we observed progressive disease.
DOI:
10.1158/1535-7163.MCT-13-0865